GSK Falls 9% Despite Q1 Earnings Beat: Buy, Hold or Exit?
GSK shares fell 9% over the past month despite reporting better-than-expected Q1 2026 results, with revenue of $8.2 billion and EPS of $0.85. Concerns over slowing legacy drug sales outweighed strong Specialty Medicines growth.
Key Numbers
GSK (NYSE: GSK) shares declined 9% over the past month, despite reporting Q1 2026 financial results that exceeded analyst expectations. Revenue reached $8.2 billion, beating estimates, while earnings per share (EPS) came in at $0.85, also above consensus. However, investors focused on slowing sales of legacy drugs, overshadowing strong growth in the Specialty Medicines segment.
Key Financial Results
| Metric | Q1 2026 | Estimate | Difference |
|---|---|---|---|
| Revenue | $8.2B | $8.0B | +2.5% |
| EPS | $0.85 | $0.80 | +6.3% |
| Specialty Medicines Growth | +15% | - | - |
| Legacy Drugs Decline | -8% | - | - |
Highlights from the Release
GSK reported 15% growth in Specialty Medicines, driven by vaccines and rare disease drugs. In contrast, Legacy Drugs sales fell 8%, impacted by patent expirations and generic competition.
Guidance
GSK did not provide specific Q2 guidance but reaffirmed its full-year revenue growth target of 5% to 7%, focusing on expanding its Specialty Medicines portfolio.
Stock Impact
The 9% monthly decline reflects investor concerns over continued Legacy Drugs erosion and uncertainty about whether Specialty Medicines can fully offset the decline.
What This Means for Investors
Investors should monitor GSK's ability to accelerate Specialty Medicines growth to compensate for legacy drug declines. Comparisons with peers like Eli Lilly (LLY) and AbbVie (ABBV) may provide sector context.
Frequently Asked Questions
Found this useful? Share it